Fierce Healthcare February 17, 2022
Variantyx’s upcoming precision oncology solution will analyze genetic alterations in a patient’s tumor to gain insights into what treatments might work best for that patient.
Precision medicine company Variantyx pulled in $41.5 million for its advanced genomic testing platform, with plans to target growth in precision oncology.
The company’s whole-genome analysis platforms, with solutions for genetic disorders, reproductive health and precision oncology, help providers gain insight into a patient’s genetic makeup to improve diagnostics and personalize treatment recommendations.
Variantyx argues that this approach reduces both emotional and financial burdens on the patient, who might otherwise have to see multiple specialists and undergo several rounds of testing before reaching a diagnosis.
“The funding is a great testament of confidence and trust...
Today's Sponsors
Today's Sponsor